Regeneron Pharmaceuticals, Inc.

The momentum for this stock is not very good. Regeneron Pharmaceuticals, Inc. is not a good growth stock. Regeneron Pharmaceuticals, Inc. is not very popular among insiders. Regeneron Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, inventio...
REGN Fundamental Data by TradingView

News

Angeles Wealth Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Angeles Wealth Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zolmax Angeles Wealth Management LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.0% during the 2nd quarter, according to the company in its most recent Form...\n more…

LGT Fund Management Co Ltd. Invests $521,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
LGT Fund Management Co Ltd. Invests $521,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ticker Report LGT Fund Management Co Ltd. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor...\n more…

EYLEA HD (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
EYLEA HD (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

Globe Newswire Three new post-hoc analyses highlight EYLEA HD rapid and sustained fluid control and consistent safety profile over two years in patients with wet age-related macular degeneration (wAMD) New...\n more…

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to "Strong-Buy" at StockNews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to "Strong-Buy" at StockNews.com

Ticker Report StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a buy rating to a strong-buy rating in a research note released on Tuesday. A number of other analysts have...\n more…

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Cantor Fitzgerald
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Cantor Fitzgerald

Zolmax Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)s stock had its "neutral" rating reissued by stock analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports...\n more…

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald

Ticker Report Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)s stock had its "neutral" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Monday, Benzinga...\n more…